OPTN Protein (Optineurin)

OPTN Protein (Optineurin)

Introduction

Optineurin (OPTN) is a 66 kDa coiled-coil domain-containing protein encoded by the OPTN gene on chromosome 10p13. Originally identified as a negative regulator of NF-κB signaling and later as an autophagy receptor for damaged mitochondria, OPTN has emerged as a critical protein in the pathogenesis of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Pathogenic mutations in OPTN cause familial ALS in approximately 1-2% of cases, making it one of the more common genetic causes of motor neuron disease[@maruyama2010].

The protein's multifaceted roles in cellular homeostasis—including selective autophagy, NF-κB signaling regulation, membrane trafficking, and mitochondrial quality control—have made it an important focus of neurodegeneration research. This comprehensive page covers OPTN's structure, normal physiological functions, disease mechanisms, and therapeutic implications.

OPTN Protein (Optineurin)

Introduction

Optineurin (OPTN) is a 66 kDa coiled-coil domain-containing protein encoded by the OPTN gene on chromosome 10p13. Originally identified as a negative regulator of NF-κB signaling and later as an autophagy receptor for damaged mitochondria, OPTN has emerged as a critical protein in the pathogenesis of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Pathogenic mutations in OPTN cause familial ALS in approximately 1-2% of cases, making it one of the more common genetic causes of motor neuron disease[@maruyama2010].

The protein's multifaceted roles in cellular homeostasis—including selective autophagy, NF-κB signaling regulation, membrane trafficking, and mitochondrial quality control—have made it an important focus of neurodegeneration research. This comprehensive page covers OPTN's structure, normal physiological functions, disease mechanisms, and therapeutic implications.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Optineurin (OPTN)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Optineurin</td></tr>
<tr><td><strong>Gene</strong></td><td>[OPTN](/genes/optn)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q96CV9](https://www.uniprot.org/uniprot/Q96CV9)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>66 kDa (577 amino acids)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>10p13</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm, Golgi, mitochondria, nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>TBK1 adaptor proteins</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>ALS, FTD, glaucoma, Paget disease of bone</td></tr>
</table>
</div>

Overview

Optineurin is a versatile adaptor protein that participates in multiple cellular pathways, including selective autophagy, NF-κB signaling, membrane trafficking, and innate immunity. The protein's ability to bind both ubiquitin chains and LC3 on autophagosomes makes it a key receptor for selective autophagy of damaged organelles and protein aggregates[@korac2013].

Key cellular functions of OPTN include:

Mutations in OPTN cause autosomal dominant ALS, often with FTD overlap, and have been associated with normal tension glaucoma and Paget disease of bone. The disease mechanism primarily involves loss of autophagic function, leading to accumulation of damaged mitochondria and protein aggregates in motor neurons[@pottier2018].

Protein Structure and Domains

Domain Architecture

Optineurin contains several distinct functional domains that mediate its diverse cellular functions[@minegishi2013]:

| Domain | Position | Function |
|--------|----------|----------|
| N-terminal domain | 1-100 | Protein interactions, TBK1 binding |
| Coiled-coil domains | 100-300 | Oligomerization, protein-protein interactions |
| LC3-interacting region (LIR) | 452-475 | LC3/GABARAP binding for autophagy |
| UBAN domain | 394-420 | Linear and Lys63-linked ubiquitin binding |
| C-terminal domain | 476-577 | Subcellular localization, additional interactions |

Structural Features

Coiled-Coil Domains: The N-terminal region (residues 1-300) contains multiple coiled-coil domains that mediate protein oligomerization. These domains allow OPTN to form homooligomers and interact with various binding partners including TBK1, myosin VI, and [huntingtin](/proteins/huntingtin). The coiled-coil structure is essential for proper protein function, and mutations in this region can disrupt oligomerization. Studies have shown that OPTN forms a parallel dimer through its coiled-coil region, with further oligomerization occurring through higher-order assembly.

LC3-Interacting Region (LIR): Located at residues 452-475, the LIR domain directly interacts with LC3 (MAP1LC3A/B) and other autophagy proteins on the forming autophagosome. The LIR contains the consensus sequence W/F/Y-XXL/I/V, which is shared by many autophagy receptors. Mutations in the LIR impair OPTN's ability to recruit autophagosomes, contributing to disease pathogenesis.

UBAN Domain: The ubiquitin-binding in ABIN and NEMO (UBAN) domain (residues 394-420) binds to linear (Met1-linked) and Lys63-linked polyubiquitin chains. This domain allows OPTN to recognize ubiquitinated cargo, including damaged mitochondria, protein aggregates, and intracellular pathogens. Ubiquitin binding is essential for OPTN's selective autophagy function, and mutations in the UBAN domain (such as p.E478G) disrupt cargo recognition.

C-terminal Domain: The C-terminal region contains additional protein interaction motifs and is involved in subcellular localization. This region also contains the TBK1 phosphorylation sites that regulate OPTN activity.

Post-Translational Modifications

OPTN activity is regulated by multiple post-translational modifications:

• Phosphorylation: TBK1 phosphorylates OPTN at multiple serine residues (Ser177, Ser473, Ser514), enhancing its ubiquitin-binding and autophagy receptor function[@richter2016]
• Ubiquitination: OPTN can be ubiquitinated at multiple sites, affecting its stability and function
• Sumoylation: SUMO modification of OPTN has been reported

Molecular Function

Selective Autophagy/Receptor

OPTN is a key autophagy receptor that bridges cargo to the autophagic machinery[@korac2013]. It recognizes ubiquitinated cargo via its UBAN domain and recruits autophagosomes via its LIR domain. OPTN-mediated selective autophagy targets include:

• Damaged mitochondria (mitophagy): OPTN recognizes ubiquitinated mitochondria and recruits autophagosomes for degradation
• Protein aggregates (aggrephagy): OPTN helps clear ubiquitinated protein aggregates
• Intracellular bacteria and viruses (xenophagy): OPTN participates in pathogen clearance
• Lipid droplets (lipophagy): OPTN contributes to lipid droplet turnover

NF-κB Signaling Regulation

OPTN interacts with NEMO (IKKγ), a key regulator of NF-κB signaling[@shen2015]. It modulates the activation of NF-κB downstream of various receptors including TNFR1, TLRs, and MDA5. OPTN can both positively and negatively regulate NF-κB depending on context, influencing inflammatory responses in [neurons](/entities/neurons) and glia.

The NF-κB regulatory function of OPTN involves:

• Binding to NEMO to modulate IKK complex activity
• Competing with other NEMO-binding proteins
• Regulating the turnover of NF-κB signaling components
• Influencing downstream gene expression

Membrane Trafficking

OPTN associates with the Golgi apparatus and participates in vesicular trafficking. It interacts with myosin VI, a motor protein that moves cargo along actin filaments. This function is important for:

• Golgi organization and function
• Protein secretion and membrane receptor trafficking
• Intracellular transport of cargo

Mitochondrial Quality Control

OPTN localizes to mitochondria and is essential for mitophagy[@wong2014]. Following mitochondrial damage:

Loss of OPTN function leads to accumulation of dysfunctional mitochondria and increased oxidative stress. This is particularly detrimental in motor neurons, which have high energy demands and limited regenerative capacity.

Innate Immune Signaling

OPTN participates in type I interferon (IFN) responses through its interaction with TBK1 and other signaling components. The OPTN-TBK1 axis is important for:

• Antiviral immune responses
• Regulation of IFN-β production
• Innate immune signaling at the mitochondria

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

OPTN mutations are responsible for approximately 1-2% of familial ALS cases and a smaller proportion of sporadic ALS[@maruyama2010]. Over 40 pathogenic OPTN variants have been identified, including missense, nonsense, and frameshift mutations.

Clinical Features

The clinical phenotype of OPTN-ALS is similar to other forms of ALS:

• Progressive limb weakness and muscle atrophy
• Bulbar symptoms (dysphagia, dysarthria)
• Respiratory insufficiency
• Disease duration: typically 2-5 years from onset

Neuropathology

• [TDP-43](/mechanisms/tdp-43-proteinopathy) proteinopathy in most cases
• Some OPTN mutations associated with ALS-FTD overlap
• OPTN-positive inclusions observed in sporadic ALS cases
• Mitochondrial dysfunction and accumulation

Pathogenic Mechanisms

The disease mechanisms involve[@pottier2018]:

Frontotemporal Dementia (FTD)

OPTN mutations have been identified in FTD patients, particularly those with motor neuron disease[@liu2024]. OPTN pathology (optineurin-positive inclusions) is observed in some sporadic FTD cases, suggesting broader involvement in disease pathogenesis.

• ALS-FTD overlap: Approximately 50% of OPTN mutation carriers develop features of both diseases
• TDP-43 pathology: Common pathological finding
• Phenotypic heterogeneity: Variable presentation within families

Normal Tension Glaucoma (NTG)

OPTN was originally identified as a gene associated with adult-onset glaucoma, particularly normal tension glaucoma[@ahmed2018]. The relationship between OPTN variants and glaucoma remains somewhat controversial, and the mechanism is distinct from neurodegeneration.

• Intraocular pressure typically normal
• Optic nerve damage and visual field loss
• May share some mechanisms with neuronal degeneration

Paget Disease of Bone (PDB)

Some OPTN mutations cause Paget disease of bone, a disorder of increased bone turnover. This reflects OPTN's role in osteoclast function and bone remodeling.

• Increased bone turnover
• Bone pain and deformity
• Usually adult onset

Mutations and Genetic Variants

Pathogenic Variants

Several OPTN mutations cause ALS and other diseases:

| Mutation | Effect on Protein | Disease | Prevalence |
|----------|-------------------|---------|------------|
| p.E478G | Disrupts ubiquitin binding | ALS | Common (founder in Japanese) |
| p.Q454X | Nonsense, truncation | ALS | Multiple populations |
| p.R545H | Impairs ubiquitin binding | ALS | UBAN domain |
| p.delExon 9 | Frameshift, loss of function | ALS | Various |
| p.H486R | Missense | Glaucoma | Unknown |
| p.M98K | Missense | Glaucoma | Common variant |

Mutation Types

• Missense mutations: Often disrupt ubiquitin binding or protein interactions
• Nonsense/frameshift mutations: Cause complete loss of function
• Splice site mutations: Lead to aberrant splicing and protein truncation

Genotype-Phenotype Correlations

• Truncating mutations: Often associated with earlier onset
• Missense mutations: Variable severity depending on functional impact
• p.E478G: Common founder mutation, disrupts UBAN function

Therapeutic Implications

Current Therapeutic Strategies

Several therapeutic strategies are being explored for OPTN-related disorders[@li2016]:

| Approach | Strategy | Status | Challenge |
|----------|----------|--------|-----------|
| Autophagy enhancement | mTOR inhibitors, AMPK activators | Preclinical | Non-specific effects |
| TBK1 modulators | Inhibitors or activators | Preclinical | Multiple substrates |
| Gene therapy | AAV-OPTN delivery | Preclinical | Delivery to CNS |
| Anti-inflammatory | NF-κB pathway modulators | Preclinical | Broad effects |
| Mitochondrial protectants | Antioxidants, CoQ10 | Preclinical | BBB penetration |

Autophagy Enhancement

Compounds that boost autophagy flux may compensate for impaired OPTN function:

• [mTOR](/mechanisms/mtor-signaling-pathway) inhibitors: Rapamycin, everolimus
• AMPK activators: Metformin, AICAR
• Natural autophagy inducers: Trehalose, resveratrol

TBK1 Modulators

Since TBK1 phosphorylates and activates OPTN, TBK1 inhibitors or activators could modulate OPTN function. However, TBK1 has multiple substrates, requiring careful targeting to avoid disrupting beneficial immune functions.

Gene Therapy

• AAV-delivered wild-type OPTN: Could restore function in loss-of-function mutations
• CRISPR-based approaches: To correct pathogenic mutations (future)
• Allele-specific targeting: For dominant mutations

Anti-inflammatory Therapies

Given the role of NF-κB dysregulation in OPTN-related diseases, anti-inflammatory agents may provide benefit by reducing neuroinflammation. However, broad immunosuppression carries risks.

Mitochondrial Protectants

Agents that protect mitochondria from oxidative damage and improve function may help compensate for impaired mitophagy:

• Coenzyme Q10
• MitoQ
• Vitamin E
• Creatine

Animal Models

OPTN Knockout Mice

Complete knockout is viable but shows:

• Age-dependent retinal degeneration
• Motor deficits with aging
• Mild neurodegeneration
• Motor neurons show mitochondrial dysfunction and increased oxidative stress[@swenson2019]

Mutant OPTN Transgenic Mice

Expressing mutant OPTN (p.E478G) causes:

• Progressive motor neuron degeneration
• Muscle weakness
• Shortened lifespan
• Recapitulate key features of human ALS

Conditional Knockout

Brain-specific knockout demonstrates that loss of OPTN in neurons is sufficient to cause neurodegeneration.

Research Directions

Current Knowledge Gaps

• Mechanism of neuronal vulnerability: Why motor neurons are particularly susceptible
• Autophagy pathway interactions: How OPTN coordinates with other autophagy receptors
• Therapeutic window: Optimal timing for intervention
• Biomarkers: Need for patient stratification and treatment response markers

Ongoing Research

• iPSC models: Patient-derived motor neurons for drug screening
• Structural studies: Cryo-EM of OPTN in complex with LC3 and ubiquitin
• Compound libraries: High-throughput screening for autophagy enhancers
• Gene therapy development: AAV delivery to CNS

Key Publications

See Also

• [OPTN Gene](/genes/optn)
• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-dementia)
• [Mitophagy](/mechanisms/pink1-parkin-mitophagy-pathway)
• [TBK1 Gene](/genes/TBK1)
• [Selective Autophagy](/mechanisms/autophagy-lysosomal-pathway)
• [NF-κB Signaling](/mechanisms/nf-kappab-signaling-neurodegeneration)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [Motor Neurons](/cell-types/spinal-motor-neurons)

External Links

• [UniProt: Q96CV9](https://www.uniprot.org/uniprot/Q96CV9)
• [NCBI Gene: OPTN](https://www.ncbi.nlm.nih.gov/gene/10133)
• [OMIM: 605432](https://www.omim.org/entry/605432)
• [ALSOD: OPTN](https://alsod.ac.uk/)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=OPTN+ALS+autophagy)

References

Pathway Diagram

The following diagram shows key molecular relationships for OPTN Protein (Optineurin) based on knowledge graph edges:

Pathway Diagram

The following diagram shows the key molecular relationships involving OPTN Protein (Optineurin) discovered through SciDEX knowledge graph analysis: